Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 19,806 | 23,335 | 21,274 | 22,312 | 24,519 |
| Cost of Goods | 7,483 | 8,070 | 6,755 | 7,710 | 12,570 |
| Gross Profit | 12,323 | 15,265 | 14,519 | 14,602 | 11,949 |
| Operating Expenses | 14,568 | 15,132 | 16,676 | 17,590 | 19,414 |
| Operating Income | -1,762 | 203 | -1,402 | -2,278 | -6,895 |
| Interest Expense | 249 | 389 | 498 | 576 | 484 |
| Other Income | -9 | -137 | 889 | -31 | 165 |
| Pre-tax Income | -2,020 | -323 | -1,011 | -2,885 | -7,214 |
| Income Tax | 27 | -64 | 66 | 38 | 12 |
| Net Income Continuous | -2,047 | -259 | -1,077 | -2,923 | -7,226 |
| Net Income | $-2,047 | $-259 | $-1,077 | $-2,923 | $-7,226 |
| EPS Basic Total Ops | -431.78 | -59.97 | -269.87 | -923.54 | -2,356.82 |
| EPS Basic Continuous Ops | -426.99 | -57.78 | -264.49 | -921.14 | -2,357.69 |
| EPS Diluted Total Ops | -431.78 | -59.97 | -269.87 | -923.54 | -2,356.82 |
| EPS Diluted Continuous Ops | -426.99 | -57.78 | -264.49 | -921.14 | -2,357.69 |
| EPS Diluted Before Non-Recurring Items | -329.84 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $1,965 | $3,287 | $975 | $645 | $-3,773 |